Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2020

November 2020 | 146 pages | ID: L1B518BD883EN
Global Markets Direct

Abstracts

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis - Pipeline Review, H2 2020, provides an overview of the Leishmaniasis (Infectious Disease) pipeline landscape.

Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Leishmaniasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leishmaniasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 15, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3, 15 and 12 molecules, respectively.

Leishmaniasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Leishmaniasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Leishmaniasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Leishmaniasis - Overview
Leishmaniasis - Therapeutics Development
Leishmaniasis - Therapeutics Assessment
Leishmaniasis - Companies Involved in Therapeutics Development
Leishmaniasis - Drug Profiles
Leishmaniasis - Dormant Projects
Leishmaniasis - Discontinued Products
Leishmaniasis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by ABIONYX Pharma SA, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Acea Biotech Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Biokawthar Technologies SAS, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by DetectoGen Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Eisai Co Ltd, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by GlaxoSmithKline Plc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Immune Modulation Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Impetis Biosciences Ltd, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI SLU, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Macrophage Therapeutics Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by MedC Biopharma Ltd, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Mind Medicine Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Molecular Targeting Technologies Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Mycosynthetix Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by NanoCliq LLC, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Pai Life Sciences Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Pfizer Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Pharos I&BT Co Ltd, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Rakta Therapeutics Inc, H2 2020
Leishmaniasis (Kala-Azar) - Pipeline by Synstar Japan Co Ltd, H2 2020
Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2020
Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2020 (Contd..1), H2 2020
Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2020 (Contd..2), H2 2020
Leishmaniasis (Kala-Azar) - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020